Short answer
PUMA BIOTECHNOLOGY, INC. (PBYI) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for the quarter ended June 30, 2026 announced.
PUMA BIOTECHNOLOGY, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for the quarter ended June 30, 2026 announced
- Full operating results and management commentary available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $56.5M, up from $52.4M, led by NERLYNX product revenue of $53.6M versus $49.2M
- Q2 GAAP net income $8.2M, or $0.16 per diluted share, versus $5.9M and $0.12
- Full-year 2026 revenue guidance raised to $224M-$231M, with net income guidance increased to $17M-$20M
- Debt reduced to zero after final 2021 Note Purchase Agreement payment, supporting financial flexibility
- Cash, equivalents and marketable securities $93.9M at June 30, while R&D rose to $38.7M through six months for alisertib development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PUMA BIOTECHNOLOGY, INC. 8-K filings
Get the next PBYI 8-K as it lands
Follow PBYI for push alerts, or ask the research agent what this filing means.